Farletuzumab is a folate receptor alpha (FRa)-targeted monoclonal antibody being developed by Eisai. It is composed of grafted murine complementarity-determining regions on a human IgG1 kappa backbone. Inhibiting FRa can decrease cellular proliferation through inhibition of both Lyn kinase substrate phosphorylation and the interaction between Lyn tyrosine kinase and membrane signaling complexes; effectively modulating processes such as cell proliferation, differentiation, apoptosis, migration, and metabolism. In ovarian tissues, inhibiting FRa with farletuzumab promoted cell lysis by both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Folate receptors have limited distribution in normal tissues, but FRa overexpression is characteristic of several tumor types including ovarian, breast, brain, lung, and colorectal cancer. FRa is overexpressed in approximately 70% of primary ovarian tumors and over 80% of recurrent tumors.
TABLE OF CONTENTS
PRODUCT PROFILES 4 farletuzumab : Ovarian cancer
LIST OF FIGURES
9 Figure 1: Farletuzumab for ovarian cancer – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment of farletuzumab for ovarian cancer
11 Figure 3: Datamonitor Healthcare’s drug assessment of farletuzumab for ovarian cancer
LIST OF TABLES
5 Table 1: Farletuzumab drug profile
6 Table 2: Farletuzumab Phase III data in ovarian cancer
9 Table 3: Ongoing farletuzumab Phase II trial in ovarian cancer
Farletuzumab is a folate receptor alpha (FRa)-targeted monoclonal antibody being developed by Eisai. It is composed of grafted murine complementarity-determining regions on a human IgG1 kappa backbone.
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726